Rhythm Pharmaceuticals Inc. (RYTM)
NASDAQ: RYTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RYTM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.79B
- EPS (TTM)
- -$2.91
- Dividend yield
- None
- 52-week range
- 74.50 – 122.20
- Day range
- 112.00 – 117.01
- Volume / Avg
- 1.50M / 1.10M
- Beta
- —
- Shares outstanding
- 69.33M
52-week range
RYTM stock today
Shares of Rhythm Pharmaceuticals (RYTM) finished lower on Nov 20 at $112.36, a drop of 3.80% or $4.44 per share, versus the S&P 500's 3.70% decline. At this level, RYTM sits in the middle of its 52-week range of $74.50 to $122.20: 8.1% below the high, set on Dec 11, 2025 and 50.8% above the low. RYTM is up 5.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.4%.
Rhythm Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.91), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Rhythm Pharmaceuticals
Company profileRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. David P. Meeker M.D.
- Headquarters
- Boston, MA
- Employees
- 414
- IPO year
- 2017
- Website
- rhythmtx.com
Financial highlights
Full financialsIn fiscal 2025, Rhythm Pharmaceuticals generated $189.8 million in revenue, up 45.8% from fiscal 2024, its 5th consecutive year of revenue growth. Rhythm Pharmaceuticals reported a net loss of $196.5 million, compared with a loss of $260.6 million a year earlier. Gross margin was 89.7% (flat year over year) and operating margin -101.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $189.76M | $130.13M | $77.43M | $23.64M | $3.15M |
| Growth | +45.83% | +68.06% | +227.56% | +649.46% | — |
| Net income | $-196.54M | $-260.60M | $-184.68M | $-181.12M | $-69.61M |
| EPS (diluted) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
Analyst forecast
ForecastConsensus (19 analysts)
strong_buy
Avg. price target
$140.12+24.71%
- Strong buy 5
- Buy 12
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.61 vs $-0.68
- Surprise
- +10.29%
RYTM news
All RYTM news- Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026GlobeNewswire
- Rhythm Pharmaceuticals gains on report of additional bidderSeeking Alpha
- Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid reportInvesting.comRYTM, AZN
- Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl SyndromeGlobeNewswire
- Rhythm Pharmaceuticals, Inc. Reports Third Quarter 2026 Net Product Revenue of $92.1 millionNasdaq
- Rhythm Pharmaceuticals GAAP EPS of -$0.61 beats by $0.10, revenue of $92.1M beats by $7.5MSeeking Alpha
- Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue EstimatesNasdaqRYTM, TECH
- Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business UpdateGlobeNewswire
Rhythm Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PTGXProtagonist Therapeutics Inc. | 121.40 | -2.11% | $7.92B | vs RYTM |
| SMMTSummit Therapeutics Inc. | 9.95 | -5.87% | $7.96B | vs RYTM |
| ALKSAlkermes plc | 44.94 | -2.69% | $7.55B | vs RYTM |
| KNSAKiniksa Pharmaceuticals International plc Class A | 93.90 | +0.38% | $7.38B | vs RYTM |
| AMRXAmneal Pharmaceuticals Inc. Class A | 21.12 | -1.26% | $7.36B | vs RYTM |
| PRAXPraxis Precision Medicines Inc. | 300.43 | -3.37% | $8.40B | vs RYTM |
| CYTKCytokinetics Incorporated | 50.78 | -1.32% | $7.07B | vs RYTM |
| CORTCorcept Therapeutics Incorporated | 63.62 | -2.09% | $6.96B | vs RYTM |
Indexes, lists and sector
Rhythm Pharmaceuticals stock FAQ
What is Rhythm Pharmaceuticals's stock price today?
RYTM last traded at $112.36 as of Nov 20, 4:00 PM EST, down 3.80% on the day. Prices are delayed at least 15 minutes.
Who is Rhythm Pharmaceuticals's CEO?
Dr. David P. Meeker M.D. is the chief executive officer of Rhythm Pharmaceuticals Inc., which has about 414 employees.
What is the RYTM 52-week high?
The 52-week high for RYTM is $122.20 and the 52-week low is $74.50. The stock is currently 8.1% below its high.